Univariate analysis for major adverse events in patients with stage C or D heart failure with non-ischaemic dilated cardiomyopathy during a 5-year follow-up
| HR | 95% CI | P value | |
| Age (years) | 1.03 | 1.00 to 1.07 | 0.0787 |
| Male | 2.77 | 0.64 to 12.04 | 0.175 |
| BMI (kg/m2) | 0.96 | 0.94 to 1.03 | 0.160 |
| Hypertension (%) | 0.81 | 0.31 to 2.10 | 0.666 |
| Diabetes mellitus (%) | 1.09 | 0.31 to 3.76 | 0.896 |
| QRS duration (ms) | 1.01 | 0.99 to 1.02 | 0.475 |
| LBBB on EKG (%) | 1.20 | 0.39 to 3.65 | 0.752 |
| RBBB on EKG (%) | 0.96 | 0.13 to 7.26 | 0.971 |
| Intraventricular block (%) | _* | _* | _* |
| ALT (U/L) | 0.98 | 0.96 to 1.01 | 0.257 |
| AST (U/L) | 0.98 | 0.94 to 1.02 | 0.344 |
| Creatinine (μmol/L) | 1.01 | 1.00 to 1.02 | 0.019 |
| Na+ (SD) (mmol/L) | 0.86 | 0.75 to 0.98 | 0.0245 |
| Cl− (SD) (mmol/L) | 0.85 | 0.76 to 0.95 | 0.005 |
| hs-CRP (mmol/L) | 1.05 | 0.98 to 1.11 | 0.150 |
| Hcy (μmol/L) | 1.00 | 0.98 to 1.01 | 0.764 |
| WBC (G/L) | 0.85 | 0.63 to 1.14 | 0.279 |
| Hb (G/L) | 1.00 | 0.98 to 1.02 | 0.724 |
| PLT (G/L) | 1.00 | 0.99 to 1.01 | 0.951 |
| BNP (Box-Cox transform) (pg/mL) | 1.57 | 1.20 to 2.04 | 0.001 |
| CMR-LVEDV (mL) | 1.00 | 1.00 to 1.01 | 0.002 |
| CMR-LVESV (mL) | 1.01 | 1.00 to 1.01 | 0.001 |
| CMR-LVEF % | 0.96 | 0.91 to 1.02 | 0.169 |
| CMR-LVMASS (g) | 1.01 | 1.00 to 1.01 | 0.161 |
| CMR-RVEDV (mL) | 1.01 | 1.00 to 1.02 | 0.045 |
| CMR-RVESV (mL) | 1.01 | 1.00 to 1.02 | 0.149 |
| CMR-RVEF % | 0.99 | 0.96 to 1.02 | 0.686 |
| CMR-LVpGLS (%) | 1.10 | 0.91 to 1.32 | 0.335 |
| CMR-LVpGCS (%) | 1.09 | 0.91 to 1.30 | 0.339 |
| CMR-RVpGCS (%) | 1.05 | 0.93 to 1.19 | 0.456 |
| CMR-RVpGLS (%) | 1.14 | 1.01 to 1.28 | 0.035 |
| CMR-LVLGE (%) | 2.57 | 0.99 to 6.68 | 0.052 |
| Medication | |||
| ACEI/ARB/ARNI (%) | 0.36 | 0.10 to 1.24 | 0.1047 |
| Beta-blocker (%) | 3.33 | 0.76 to 14.53 | 0.1092 |
| Spironolactone (%) | 0.52 | 0.07 to 3.92 | 0.5258 |
BNP has done the Box-Cox transformation whose formula is (BNPˆ0.1418–1)/0.1418.
*The model failed because of the small sample size.
ACEI, ACE inhibitor; ALT, alanine transaminase ; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; AST, aspartate transaminase; BMI, body mass index; BNP, brain natriuretic peptide; CMR, cardiac magnetic resonance; Hb, haemoglobin; Hcy, homocysteine; hs-CRP, high-sensitivity C reactive protein; LBBB, left bundle branch block; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVLGE, left ventricular late gadolinium enhancement; LVMASS, left ventricular mass; LVpGCS, left ventricular peak global circumferential strain; LVpGLS, left ventricular peak global longitudinal strain; PLT, platelets; RBBB, right bundle branch block; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVpGCS, right ventricular peak global circumferential strain; RVpGLS, right ventricular peak global longitudinal strain; WBC, white blood cell.